EDF Health

Evidence mounts on BPA’s adverse effects on human health

Lindsay McCormick is a Research Analyst.

Bisphenol A (BPA) is a high production volume chemical that is used to make polycarbonate plastics and epoxy resins.  It is commonly found in food and beverage packaging, such as plastic bottles and the lining of food cans, as well as thermal paper receipts (see our previous blog).  BPA is widely-recognized as an endocrine-disrupting chemical, meaning that it can alter the normal functioning of the body’s hormonal system.  Hundreds of studies have been published associating BPA exposure with health effects, ranging from cancer to obesity to attention-deficit hyperactivity disorder.  Data from the Center for Disease and Control (CDC) show that nearly all people tested have BPA in their bodies.

Despite a plethora of data, numerous calls for action (for example, see here, here and here), and comprehensive regulation in France, it does not seem that national regulation of BPA in food packaging in the U.S. will be happening any time soon.  The official position of the U.S. Food and Drug Administration (FDA) is that, while BPA exhibits endocrine-disrupting properties at high doses, it is safe at the current levels occurring in food.  Although the FDA banned the use of BPA-based materials in baby bottles, sippy cups, and infant formula packaging in 2012, FDA said it based this action on changes in the market, rather than safety concerns.

In the fall of 2014, FDA completed a four-year review of the literature, including more than 300 scientific studies, and concluded that the information does not “prompt a revision of FDA’s safety assessment of BPA in food packaging at this time.”

The European Food Safety Authority (EFSA) recently followed suit with their announcement that BPA does not pose a health risk to consumers, including children, at current exposure levels.  (This is in contrast to the action of several EU member states, which have banned BPA in food contact materials for children under 3 years of age over the past few years.)

Meanwhile, scientists continue to churn out studies linking low-level BPA exposure to a variety of health effects.  In this post, we discuss several new studies.   Read More »

Posted in Emerging Science, Health Science| Tagged , | Comments are closed

Getting under the surfac-tants: EDF comments support EPA regulations to limit their risks

Lindsay McCormick is a Research AnalystRichard Denison, Ph.D., is a Lead Senior Scientist

Today EDF submitted comments supporting EPA’s proposal to limit the use of two groups of toxic chemicals that have historically been widely used as, or to make, surfactants in consumer and commercial cleaning products.  The chemicals, nonylphenols (NPs) and nonylphenol ethoxylates (NPEs), are produced in high volumes for a variety of industrial uses and consumer products, some of which have led to widespread water pollution.  The chemicals are highly toxic to aquatic organisms, and also pose significant potential human health risks.

In October, EPA proposed a Significant New Use Rule (SNUR) for these chemicals that would require any company intending to begin manufacture or import of these chemicals to notify EPA prior to doing so, thereby allowing EPA to evaluate the risks associated with the proposed use of the chemical and to take action if appropriate.

SNURs are one of the few regulatory tools that EPA has to seek to restrict the use of chemicals under the nation’s outdated chemical safety law, the Toxic Substances Control Act (TSCA).

While EDF’s comments generally support EPA’s proposed rule, they also raise some concerns.  Some highlights of our comments are described below.   Read More »

Posted in EPA, Health Policy, Health Science| Tagged , , | Comments are closed

What I Learned from Theo Colborn

Sarah Vogel, Ph.Dis Director of EDF's Health Program.

It was late September and we were driving up and over the Kebler Pass, which takes you from the dry desert environment of the Western Slope of the Rocky Mountains near Paonia, Colorado to the high mountain town of Crested Butte. We traveled through green meadows up through groves of quaking aspens, bright gold at the higher altitudes, up towards the pass, already covered in snow, blindingly bright under a brilliant Colorado sun and clear blue sky.

These were the mountain ranges where Theo Colborn, scientist and environmental health advocate, began her studies; where she lived for much of her life; the mountains that she loved; where she recently passed away at 87 years of remarkable age; and, where I suspect her spirit now resides.

Read More »

Posted in Emerging Science, Health Policy, Health Science| Tagged , | Read 1 Response

EPA IRIS program requests conflict-of-interest disclosures by commenters

Richard Denison, Ph.D.is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst

EPA’s Integrated Risk Information System (IRIS) is now requesting that persons who make oral comments at its bimonthly meetings or submit written comments on its documents disclose whether they have “financial relationships … with any organization(s) or entities having an interest in the assessments or issues under discussion,” and, if so, to identify the nature of that relationship, (e.g., consulting agreements, expert witness support, or research funding).   Read More »

Posted in Health Policy, Industry Influence| Tagged , | Comments are closed

Whither TSCA reform post-election?

Richard Denison, Ph.D., is a Lead Senior Scientist.

[This post is adapted from comments I gave at a recent Friday Forum hosted by the American Bar Association’s Pesticides, Chemical Regulation and Right-to-Know Committee.]

Elections change some things and don’t change others.  That is certainly true about what happened on Nov 4.

The best election recap I’ve heard came from a hairdresser I overhead when getting my hair cut last week.  She said:  “Democrats win, I have to work; Republicans win, I have to work.”

I doubt anyone would try to argue that the election was in any way about or directly relevant to the TSCA reform debate, or even any sort of more general referendum on the environment.  My view is that it wasn’t really even much about political parties and which one controls the Senate – it was more of a “throw the bums out and let some new ones have a try” election.

On the other hand, it was about broad and deep dissatisfaction of voters with the inability of Washington to get anything meaningful done.  That is relevant to the opportunity the TSCA reform issue presents to the new Congress, which is one of a handful of issues that seems to have the potential to show voters that something can get done.

There is also no question that the dynamics that have determined for some time the pace and direction of the TSCA reform debate changed significantly with the switch to Republican control of the Senate. That brings with it new political opportunities and challenges.

But what I want to talk mostly about is what HASN’T changed.  Read More »

Posted in Health Policy, TSCA Reform| Tagged | Comments are closed

EDF’s recommendations for IRIS conflicts-of-interest disclosures, and the strong precedents for them

Richard Denison, Ph.D., is a Lead Senior Scientist.  Lindsay McCormick is a Research Analyst

Our last blog post was quite lengthy and some readers may not have gotten to the recommendations we provided to EPA’s Integrated Risk Information System (IRIS) governing disclosures of conflicts of interest.  In that post, we also cited the numerous strong precedents for requiring such disclosures.

So we’re reposting here our recommendations and discussion of precedents.   Read More »

Posted in Health Policy, Industry Influence| Tagged , , | Comments are closed
  • About this blog


    Science, health, and business experts at Environmental Defense Fund comment on chemical and nanotechnology issues of the day.
    Our work: Chemicals
  • Categories

  • Get blog posts by email

    Subscribe via RSS

  • Filter posts by tags

    • aggregate exposure (10)
    • Alternatives assessment (3)
    • American Chemistry Council (ACC) (57)
    • arsenic (3)
    • asthma (3)
    • Australia (1)
    • biomonitoring (9)
    • bipartisan (6)
    • bisphenol A (21)
    • BP Oil Disaster (18)
    • California (1)
    • Canada (7)
    • carbon nanotubes (24)
    • carcinogen (22)
    • Carcinogenic Mutagenic or Toxic for Reproduction (CMR) (12)
    • CDC (6)
    • Chemical Assessment and Management Program (ChAMP) (13)
    • chemical identity (30)
    • chemical testing (1)
    • Chemicals in Commerce Act (3)
    • Chicago Tribune (6)
    • children's safety (23)
    • China (10)
    • computational toxicology (11)
    • Confidential Business Information (CBI) (53)
    • conflict of interest (7)
    • consumer products (49)
    • Consumer Specialty Products Association (CSPA) (4)
    • contamination (4)
    • cumulative exposure (4)
    • data requirements (46)
    • dermal exposure (1)
    • Design for Environment (1)
    • diabetes (4)
    • DNA methylation (4)
    • DuPont (11)
    • endocrine disruption (30)
    • epigenetics (4)
    • exposure and hazard (49)
    • FDA (9)
    • flame retardants (20)
    • formaldehyde (15)
    • front group (13)
    • general interest (22)
    • Globally Harmonized System (GHS) (5)
    • Government Accountability Office (5)
    • hazard (6)
    • High Production Volume (HPV) (23)
    • in vitro (14)
    • in vivo (11)
    • industry tactics (44)
    • informed substitution (1)
    • inhalation (18)
    • IUR/CDR (27)
    • Japan (3)
    • lead (6)
    • markets (1)
    • mercury (4)
    • methylmercury (2)
    • microbiome (3)
    • nanosilver (6)
    • National Academy of Sciences (NAS) (20)
    • National Institute for Occupational Safety and Health (NIOSH) (7)
    • National Institute of Environmental Health Sciences (NIEHS) (5)
    • National Nanotechnology Initiative (NNI) (7)
    • National Toxicology Program (1)
    • obesity (6)
    • Occupational Safety and Health Administration (OSHA) (3)
    • Office of Information and Regulatory Affairs (OIRA) (4)
    • Office of Management and Budget (OMB) (16)
    • Office of Pollution Prevention and Toxics (OPPT) (3)
    • oil dispersant (18)
    • PBDEs (16)
    • Persistent Bioaccumulative and Toxic (PBT) (22)
    • pesticides (7)
    • phthalates (17)
    • polycyclic aromatic hydrocarbons (PAH) (5)
    • prenatal (6)
    • prioritization (35)
    • report on carcinogens (1)
    • revised CSIA (4)
    • risk assessment (69)
    • Safe Chemicals Act (24)
    • Safer Chemicals Healthy Families (33)
    • Significant New Use Rule (SNUR) (20)
    • Small business (1)
    • snur (1)
    • South Korea (4)
    • styrene (6)
    • Substances of Very High Concern (SVHC) (15)
    • systematic review (1)
    • test rule (18)
    • tributyltin (3)
    • trichloroethylene (TCE) (4)
    • Turkey (3)
    • U.S. states (14)
    • vulnerable populations (1)
    • Walmart (2)
    • worker safety (23)
    • WV chemical spill (11)